BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17145884)

  • 1. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
    Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
    Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.
    Torres-Arzayus MI; Font de Mora J; Yuan J; Vazquez F; Bronson R; Rue M; Sellers WR; Brown M
    Cancer Cell; 2004 Sep; 6(3):263-74. PubMed ID: 15380517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
    Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
    Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis.
    Kuang SQ; Liao L; Wang S; Medina D; O'Malley BW; Xu J
    Cancer Res; 2005 Sep; 65(17):7993-8002. PubMed ID: 16140972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
    Zhang H; Stephens LC; Kumar R
    Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
    De Angel RE; Conti CJ; Wheatley KE; Brenner AJ; Otto G; Degraffenried LA; Hursting SD
    Mol Carcinog; 2013 Jun; 52(6):446-58. PubMed ID: 22290600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
    Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.
    Kuang SQ; Liao L; Zhang H; Lee AV; O'Malley BW; Xu J
    Cancer Res; 2004 Mar; 64(5):1875-85. PubMed ID: 14996752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
    Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
    Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.